Eyeworld Daily News

23 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, Los Angeles 2017 a view; using microforceps to grasp the CTR instead; releasing the CTR into the bag; using the CTR as late as you can and as early as you must; having a backup plan, such as cap- sular hooks; and considering scleral fixation in the form of a sutured ring or segment or a glued capsular hook, the latter of which Dr. Jacob noted is an off-label use. The TOPGUN award, presented to the best overall instructor, went to Robert "Pacman" Ang, MD, Manila, Philippines, who spoke about an easy, readily available, and relatively inexpensive capsule mark- ing technique. First, he explained the importance of a consistent and appropriately sized and centered capsulorhexis. Femto and digital markers can be expensive, not avail- able to everyone, and sometimes not entirely easy to use. Instead, Dr. Ang suggested using an optical zone marker, typically used for refractive surgery. It creates a small indent that fades; it's customizable in that you could buy several different sizes; and it's easily accessible to everybody. The overall best instructor team award was presented to APACRS, which, in addition to Drs. Ang, Jacob, and Oshika, included John "Dragon" Chang, MD, Hong Kong, Soon Phaik "Spice Girl" Chee, MD, Singapore, Y.C. "Merlin" Lee, MD, Perak, Malaysia, and Michael "Gladiator" Lawless, MD, Sydney, Australia. Kerry "POTUS" Solomon, MD, Mount Pleasant, South Carolina, on the ASCRS team, presented video evidence of the benefit of using an aspirating speculum. Using model eyes and dye—one eye with a regu- lar speculum and another eye with an aspirating one—Dr. Solomon showed how in various stages of cataract surgery, dye in the non-as- pirating speculum was able to enter the eye in greater quantities. While in a clinical setting, sur- geons might not think twice about the unintentional fluid entering the eye because they can't see it, "what are we introducing into the eye when we introduce this?" Dr. Solomon asked. "Meibomian secretions, tear film debris, inflammatory mediators, and potentially microorganisms" could Indication LOTEMAX ® GEL (loteprednol etabonate ophthalmic gel) 0.5% is indicated for the treatment of post-operative infl ammation and pain following ocular surgery. Important Safety Information about LOTEMAX ® GEL • LOTEMAX ® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. • Use of corticosteroids may result in posterior subcapsular cataract formation. • Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, and where appropriate, fluorescein staining. • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infection. • Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. • Patients should not wear contact lenses when using LOTEMAX ® GEL. • The most common ocular adverse drug reactions reported were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%). Please see brief summary of Prescribing Information on adjacent page. ®/™ are trademarks of Bausch & Lomb Incorporated or its a liates. © 2015 Bausch & Lomb Incorporated. All rights reserved. Printed in USA. US/LGX/15/0041(1) Down, Boy. Help Tame Postoperative Ocular Inflammation and Pain With LOTEMAX ® GEL continued on page 24 Dr. Oshika presented his simple chamber maintenance technique "goldfinger" and was awarded the Great Balls of Fire award.

• Cover